Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.811 USD | +1.38% | -12.84% | -1.23% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.23% | 79.16M | |
+33.04% | 698B | |
+26.51% | 568B | |
-4.33% | 358B | |
+19.12% | 328B | |
+3.88% | 283B | |
+16.42% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.39% | 165B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Transcript : HOOKIPA Pharma Inc. - Special Call